医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mannatech Announces Official Completion of the M5M℠ China Run

2014年11月12日 AM01:00
このエントリーをはてなブックマークに追加


 

COPPELL, Texas

Mannatech®, Incorporated (NASDAQ: MTEX), the pioneer of nutritional glycobiology, leading innovator of naturally-sourced supplements based on Real Food Technology® solutions, and creator of the M5M (Mission 5 MillionSM) social entrepreneurial movement, announced today that on October 28, 2014, ultra-endurance athlete Jason Lester officially passed the finish line of the M5M China Run. Lester became the first person in history to complete a solo run of 2,500 miles across the Great Wall of China in 100 days or less to raise awareness of the global epidemic of childhood malnutrition.

The run officially began on August 8, 2014 in Jiayuguan, in the Gansu province of China. Around midday on day 83 of the run, Lester crossed the finish line at the Shanhaiguan District Old Dragons Head entrance in Qinhuangdao, Hebei province, officially completing the 2,500-mile journey. Lester’s goal was to finish the run within 100 days, requiring an average daily trek equivalent to almost a full marathon per day. After increasing his daily runs to double marathons at times, he was able to accomplish this feat with 17 days to spare.

Mannatech has partnered with Lester as the title sponsor of the M5M China Run as a part of their ongoing Mission 5 Million, or M5M, movement. The goal of M5M is to connect five million children in need of proper nutrition with five million consumers of Mannatech products. As a social entrepreneurial company, Mannatech donates servings of its proprietary PhytoBlend™ powder to at-risk children all over the world every time a consumer purchases product for themselves on automatic order. According to recent reports by the World Health Organization, approximately five million children under the age of 5 die every year due to causes linked to malnutrition. As the title sponsor, Mannatech is hoping to bring this catastrophic reality to the forefront and inspire the world to take action.

Lester has previously run 3,500 miles from San Francisco to New York in 2013 to raise awareness and support for the victims of Hurricane Sandy; and in 2011 he biked and ran 5,000 miles across the United States for Nike’s “Journey for a Better World” campaign. Lester is an endorser of Mannatech products and is “Powered by Ambrotose,” Mannatech’s uniquely patented immune system support product containing Manapol® powder with aloe vera gel extract. He credits glyconutrient technology and Ambrotose as being his “secret weapons” in competitions and training.

“We are very proud of Jason Lester for achieving such a monumental feat and are grateful for the impact he made on the M5M movement,” said Mannatech President Al Bala. “His ambitious drive to be better and make the world a better place matches Mannatech’s desire to see childhood malnutrition come to an end through perseverance and commitment to daily challenges such as Jason Lester’s 100-Day Challenge. Through his efforts in bringing awareness to this cause, we are able to tackle the great wall of malnutrition head on with hope of seeing it overcome.”

To learn more about Mannatech and the M5M China Run, visit Mannatech.com.

About Mannatech

Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing nutrition where it is needed most around the world. Mannatech’s proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea, Mexico, Namibia and Hong Kong. For more information, visit Mannatech.com.

Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “believe,” “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain Associates and Members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

CONTACT

Mannatech, Incorporated
Raquel Mooring, 972-471-1532
rmooring@mannatech.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent